Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia- parkinsonism

Annals of Neurology

Volumn 43, Issue 4, 1998, Pages 521-526

  Brashear, Allison ^a,f   Butler, Ian J ^b   Hyland, Keith ^c,d   Farlow, Martin R ^a   Dobyns, William B ^e  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; NORADRENALIN; SEROTONIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; DYSTONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; PARKINSONISM; PEDIGREE; PRIORITY JOURNAL;

ADULT; AGED; ANTIPARKINSON AGENTS; BIOLOGICAL MARKERS; DEGLUTITION DISORDERS; DOPAMINE; DYSARTHRIA; DYSTONIA; FEMALE; HETEROZYGOTE DETECTION; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NOREPINEPHRINE; PARKINSON DISEASE; PEDIGREE; SEROTONIN; TIME FACTORS;

EID: 0031780914     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430417     Document Type: Article

References (15)

1. Dobyns WB, Ozelius LJ, Kramer PL, et al. Rapid-onset dystonia-parkinsonism. Neurology 1993;43:2596-2602
2. Brashear A, Farlow MR, Butler IJ, et al. Variable phenotype of rapid-onset dystonia-parkinsonism. Mov Disord 1995;11:157-162
3. Brashear A, DeLeon D, Bressman S, et al. Rapid-onset dystonia-parkinsonism: a report of a second family. Neurology 1997;48:1066-1069
4. Seifert WE, Foxx JL, Butler IJ. Age effect on dopamine and serotonin metabolite levels in cerebrospinal fluid. Ann Neurol 1980;8:38-42
5. Hyland K, Surtees R, Rodeck C, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1991;42:198-1988
6. Howells DW, Smith I, Hyland K. Estimation of tetrahydrobiopterin and other pterins in cerebrospinal fluid using reversed-phase high-performance liquid chromatography with electrochemical and fluorescence detection. J Chromatogr 1986; 381:285-294
7. The Parkinson's Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995;52:237-245
8. LeWitt PA, Galloway MP, Matson W, et al. Markers of dopamine metabolism in Parkinson's disease. Neurology 1992;42: 2111-2117
9. Nygaard T. Dopa-responsive dystonia: delineation of the clinical syndrome and clues to pathogenesis. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology. New York: Raven Press, 1993:577-585
10. Ishikawa A, Miyatake T. A family with hereditary juvenile dystonia-parkinsonism. Mov Disord 1995;10:482-488
11. Chase TN. Neurochemical alterations in Parkinson's disease. In: Wood JH, ed. Neurobiology of cerebrospinal fluid. New York: Plenum Press, 1980:207-218
12. Lüdecke B, Dworniczak B, Bartholomé. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. Hum Genet 1995;95:123-125
13. Howells DW, Hyland K. Direct analysis of tetrahydrobiopterin in cerebrospinal fluid by high-performance liquid chromatography with redox electrochemisty: prevention of autoxidation during storage and analysis. Clin Chem Acta 1987;167:23-3
14. Hornykiewicz O. Metabolism of brain dopamine in human parkinsonism: neurochemical and clinical aspects. In: Yahr MD, Costa E, Coté L, eds. Biochemistry and pharmacology of the basal ganglia. New York: Raven Press, 1966:171-185
15. Tohgi H, Abe T, Takahashi S, et al. Monamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent thetapeutic outcomes. J Neural Transm 1993;5:17-26